Transcatheter closure of patent foramen ovale using the internal jugular venous approach

Similar documents
Percutaneous atrial septal defect closure with the Occlutech Figulla Flex ASD Occluder.

Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health

Fabien Praz, Andreas Wahl, Sophie Beney, Stephan Windecker, Heinrich P. Mattle*, Bernhard Meier

For Personal Use. Copyright HMP 2013

PFO Management update

RESPECT Safety Findings

Type Size AP/PS RP/RS Qp/Qs. Ia Resistive <0.3 < Ib Resistive <0.3 < IIa Resistive <0.5 >2

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

2D/3D in Evaluation of Atrial Septum

Patent foramen ovale (PFO) is composed of

Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.

Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?

ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY

Clinical Commissioning Policy Statement: Patent Foramen Ovale (PFO) Closure. April Reference: NHSCB/A09/PS/a

UNMH Pediatric Cardiology Clinical Privileges. Name: Effective Dates: From To

Adult Echocardiography Examination Content Outline

Diversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia

Devices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP

GERIATRICS CASE PRESENTATION

PFO closure group total no. PFO closure group no. of males

PATENT FORAMEN OVALE: UPDATE IN MANAGEMENT OF RECURRENT STROKE KATRINE ZHIROFF, MD, FACC, FSCAI LOS ANGELES CARDIOLOGY ASSOCIATES

ACUTE CENTRAL PERIFERALEMBOLISM

PFO- To Close for Comfort. By: Vincent J.Caracciolo, MD FACC

For Personal Use. Copyright HMP 2013

Concomitant procedures using minimally access

CPAG Summary Report for Clinical Panel Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke

Intracardiac echocardiography: an ideal guiding tool for device closure of interatrial communications

Effect of Having a PFO Occlusion Device in Place in the RESPECT PFO Closure Trial

Percutaneous closure of a patent foramen ovale after cryptogenic stroke

Trans-septal Catheterization. December 8, Jonathan Tobis, MD Professor of Medicine Interventional Cardiology, UCLA

BASIL D. THANOPOULOS MD, PhD Associate Professor Honorary Consultant, RBH, London, UK

Percutaneous VSD closure

EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC

2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.

Patent Foramen Ovale: Diagnosis and Treatment

Cryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare

Corporate Medical Policy

The earliest application of intracardiac imaging

Hybrid Muscular VSD Closure in Small Weight Children

I, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real

Anaesthesia for percutaneous closure of atrial septal defects Patrick A Calvert BCh MA MRCP Andrew A Klein MBBS FRCA

Atrial Septal Defect Closure. Stephen Brecker Director, Cardiac Catheterisation Labs

A case of mislabeled textbooks: misnomer of the traditional "bicaval" view.

Patent Foramen Ovale Closure Without Echocardiographic Control: Use of Standby Intracardiac Ultrasound

INSTRUCTIONS FOR USE FOR:

PFO (Patent Foramen Ovale): Smoking Gun or an Innocent Bystander?

PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL

CLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence

Transcatheter Closures for Fistula Tract and Paravalvular Leak after Mitral Valve Replacement and Tricuspid Annuloplasty

Device Closure of ASD in Children Using the Amplatzer Devices: Indications and catheter preparations, technique, and outcome [15]

Γεώργιος Δ. Κατσιμαγκλής. Αν. Διευθυντής Καρδιολογικής ΚλινικήςΝΝΑ Διευθυντής Αιμοδυναμικού Εργαστηρίου ΝΝΑ

Expanding Horizons: AngioVac Suction Thrombectomy at UTHealth

Echocardiographic Guidance During Placement of the Buttoned Double-Disk Device for Atrial Septa1 Defect Closure

Patient guide: pfm Nit-Occlud PDA coil occlusion system. Catheter occlusion of. Patent Ductus Arteriosus. with the

THINK OUTSIDE THE PILLBOX

THINK OUTSIDE THE PILLBOX

Transcatheter aortic valve replacement with intracardiac echocardiography from the right internal jugular vein

In October 2016, the US Food and Drug Administration

Multifenestrated Septal Occluder Cribriform

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Transcatheter Aortic Valve Implantation Procedure (TAVI)

CY2017 Hospital Outpatient: Vascular Procedure APCs and Complexity Adjustments

A challenging case of successful ASD closure without echocardiographic guidance in an 86-year old with severe kyphoscoliosis and platypnoeaorthodeoxia

Atrial fibrillation (AF), one of the

Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device

TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO

CY2015 Hospital Outpatient: Endovascular Procedure APCs and Complexity Adjustments

Intracardiac EchoCardiography (ICE) Common Views

Technique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,

Cryptogenic Stroke: A logical approach to a common clinical problem

Update interventional Cardiology Hans Rickli St.Gallen

TEACHING CASE # 5. Reocclusion Of Transverse And Sigmoid Venous Sinuses Mechanical and Chemical Thrombectomy

Transcatheter Closure of Septal Defects

Atrial Septal Defects

PFO Closure is a Therapy for Migraine PRO

Cigna - Prior Authorization Procedure List Cardiology

Διαδερμική θεραπεία των παραβαλβιδικών διαφυγών Σ.Ράμμος

AMPLATZER Septal Occluder

INTEGRATING ECHOCARDIOGRAPHY WITH CATHETER INTERVENTIONS FOR CONGENITAL HEART DISEASE. Krishna Kumar SevenHills Hospital, Mumbai, India

Interesting Cases - A Case Report: Renal Cell Carcinoma With Tumor Mass In IVC And Heart. O Wenker, L Chaloupka, R Joswiak, D Thakar, C Wood, G Walsh

Muscular VSD Occluder

Clinical Policy: Transcatheter Closure of Patent Foramen Ovale Reference Number: CP.MP.151

National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION. Original Date: October 2015 Page 1 of 5

ER REBOA Catheter. Instructions for Use

TCTAP C-217 Bilateral Pulmonary Arterio Venus Fistula Managed by Vascular Plugs and Coil Manotosh Panja 1 1 BelleVue Clinic, India

Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France

JOINT MEETING 2 Tricuspid club Chairpersons: G. Athanassopoulos, A. Avgeropoulou, M. Khoury, G. Stavridis

ThruPort systems ProPlege peripheral retrograde cardioplegia device

Current management aspects in adult congenital heart disease: non-surgical closure of patent foramen ovale

You Won t Believe What I Saw on. Disclosures. Goals. Dimensions 2013 October 18 th Michael Pfeiffer, MD. No Financial Disclosures

Girish M Nair, Seeger Shen, Pablo B Nery, Calum J Redpath, David H Birnie

Multidetector computed tomography in the evaluation of atrial septal defects

Transcatheter closure of the patent ductus arteriosus using the new Amplatzer duct occluder: Initial clinical applications in children

Nit-Occlud. Coil System for PDA Closure IMPLANTATION POCKET GUIDE. Rx only CV / B. Braun Interventional Systems Inc.

Why Should We Treat PFO?

Implantation of Cardioverter Defibrillator After Percutaneous Closure of Atrial Septal Defect

Originally Posted: November 15, 2014 BRUIT IN THE GROIN

Migraine and Patent Foramen Ovale (PFO)

SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY

The Adolescent and Adult Congenital Heart Disease Program

Transcription:

New methods in diagnosis and therapy Transcatheter closure of patent foramen ovale using the internal jugular venous approach Przemysław Węglarz 1,2, Ewa Konarska-Kuszewska 2, Tadeusz Zębik 2, Piotr Kuszewski 1, Agnieszka Drzewiecka-Gerber 4, Marek Motyka 5, Tomasz Ludyga 3, Grzegorz Bajor 1 1 Department of Human Anatomy, Silesian University of Medicine, Katowice, Poland 2 Department of Cardiology, Euromedic, Katowice, Poland 3 Euromedic Medical Center, Katowice, Poland 4 American Heart of Poland, Ustron, Poland 5 Department of General and Vascular Surgery, Regional Specialist Hospital No. 4, Bytom, Poland Abstract Postep Kardiol Inter 2014; 10, 2 (36): 123 127 DOI: 10.5114/pwki.2014.43520 Transcatheter closure of patent foramen ovale is routinely performed using the transfemoral approach, which is safe and technically easy. Our case represents the rare situation where the procedure needs to be performed using the right internal jugular venous approach. According to our best knowledge this is the first report of a patent foramen ovale closure procedure with access through the internal jugular with necessity to advance the guide wire and transseptal sheath into the left ventricle. Developing alternative techniques of transcatheter patent foramen ovale closure seems to be especially important in rare cases where transfemoral access is unavailable. Key words: paradoxical embolism, thromboembolism, patent foramen ovale. Introduction Transcatheter closure of patent foramen ovale (PFO) is a standard procedure at many health centers worldwide. The indication for this treatment is usually cryptogenic stroke with high probability of paradoxical embolism as its cause. The procedure is routinely performed using the transfemoral approach. This approach allows for relatively quick and safe implantation of the septal occluder. In contrast, other than femoral approaches are rarely used and are potentially difficult [1 4]. Our case was a situation in which the procedure needed to be performed using the right internal jugular venous approach with further procedure modification requiring wire and transseptal sheath advancement to the left ventricle. Case report A 26-year-old man with an 8-year history of venous thromboembolism and Crohn s disease with protein C deficiency was admitted to our center to consider percutaneous closure of patent foramen ovale. After a history of an ischemic neurological event with right hemiparesis in April 2013 (computed tomography scan of the head revealed no lesions of vascular origin), the patient was suspected to have an atrial septal defect, with an indication of urgent cardiological diagnostics. Transesophageal echocardiography (TEE) revealed presence of PFO associated with an atrial septal aneurysm (ASA) and Chiari network, with massive right-to-left shunting of contrast (agitated saline) during the Valsalva maneuver. Since the diagnosis of thromboembolic disease, the patient has been systematically monitored by a vascular surgeon. He was repeatedly hospitalized for aggravation of symptoms. Clinical imaging (angio-computed tomography) in 2005 revealed massive thrombi in the femoral and iliac veins and inferior vena cava (IVC) at the level of the aortic bifurcation. Subsequently after PFO diagnosis, inferior vena cava occlusion with prominent venous collaterals and dilatated hepatic veins was revealed. The patient was qualified for percutaneous closure of the PFO with the following indications: (1) long-term history of thromboembolic disease which is a direct risk factor for paradoxical embolism in patients with PFO; (2) anatomy of the PFO massive right-to-left shunting during the Corresponding author: Piotr Kuszewski MD, Department of Human Anatomy, Silesian University of Medicine, 18 Medyków St, 40-762 Katowice, Poland, phone: +48 601 365 215, e-mail: kuszepio@gmail.com Received: 23.12.2013, accepted: 7.05.2014. 123

A B Figure 1. Anatomic preparation showing the channel of the foramen ovale physiologically directed towards the inferior vena cava. JL 3.5 catheter inserted into the PFO through the superior vena cava (black arrow) and typical access with the catheter advanced through the inferior vena cava (white arrow) Valsalva maneuver, the presence of ASA and Chiari network; (3) history of transient ischemic attack with right hemiparesis; (4) potential surgical treatment of the vascular system of the IVC and the hepatic veins. Due to the inability to perform the procedure through the classical femoral venous access, a right internal jugular venous approach was planned. The intervention was performed under general anesthesia and TEE control. A 6 Fr sheath was placed in the right internal jugular vein using the Seldinger technique, followed by a 0.035 vascular guidewire. The main difficulty in the course of the intervention was passing through the PFO into the left atrium (LA), which required curving the catheter superiorly and rotating it in the direction of the PFO channel (Figure 1). Initial attempts to probe the PFO using multiple catheters (Cordis Amplatz Right 1MOD, Cordis Amplatz Left 3, Cordis Internal Mam- Figure 2. The black arrow marks a part of the JL 3.5 catheter located in the superior vena cava, the white arrow shows where the catheter passes through the interatrial septum. X-ray spectroscopy (A) and transesophageal echocardiography (B) mary, Cordis Judkins Right 4) were unsuccessful. Finally, using a JL 3.5 guiding catheter and a Terumo 260 Guide Wire M 0.035 hydrophilic guidewire allowed passing through the PFO channel into the left atrium (Figure 2). In the next step, an Amplatz Ultra Stiff Wire Guide with a specially wrapped tip was passed through the JL 3.5 guide. The attempt to fix the wire in the left atrium was unsuccessful, so a decision was made to advance the wire through the mitral valve into the left ventricle (Figure 3). Then, a 9 Fr sheath, nominally used with the Occlutech Figulla sets, was cautiously advanced over the wire into the LV (Figure 4). To close the PFO, the Figulla Flex II PFO 23/25 mm occluder device was selected due to its attachment mech- 124

Figure 4. 9 Fr transseptal sheath with distal end in the left ventricle Figure 3. Amplatz Ultra Stiff Wire Guide with a wrapped tip positioned in the left ventricle anism which allows the device to be placed at an acute angle to the delivery system, with minimal tension on the interatrial septum (IAS) directly after implanting the occluder. After carefully withdrawing the sheath above the mitral valve, the left atrial disk of a Figulla Flex II PFO 23/25 mm occluder device was opened (Figure 5) and pulled upon the interatrial septum. Through withdrawing the sheath the right atrial disk was deployed. After confirming proper apposition of the occluder by fluoroscopy and TEE, it was released from the delivery system (Figures 6 and 7). The procedure was performed using routine antibiotic cover and anticoagulation. The patient received a loading dose of clopidogrel (300 mg) and 75 mg of aspirin. As a continuation of treatment clopidogrel and aspirin in a dose of 1 75 mg were prescribed for 6 months. Control transthoracic echocardiography (TTE) performed one and 2 days after the procedure showed correct position of the occluder on the interatrial septum. During hospitalization, the patient suffered from a non-convulsive epilepsy attack. A computed tomography scan of the head excluded embolic etiology. The episode resolved after conventional treatment without any neurological deficits. The consulting neurologist recommended further diagnostics for epilepsy in a neurology outpatient clinic. The patient was discharged home on the second day after the pro- Figure 5. Arrow marks the left atrial disk while being advanced towards the interatrial septum cedure. During a 3-month follow-up the patient was free of any neurological symptoms and TTE revealed proper position of the occluder on the interatrial septum. 125

Figure 7. Transesophageal echocardiography image of the occluder immediately after implantation (white arrow) Figure 6. Occluder immediately after implantation (black arrow). 9 Fr sheath visible in the superior vena cava (white arrow) Discussion Results of randomized clinical trials, announced last year, on the one hand do not present a conclusive answer to the question of the benefit of performing percutaneous PFO closure, and on the other hand suggest that PFO closure procedures will become a permanent feature in cryptogenic stroke prevention, especially in young patients. These procedures are commonly performed and access through the femoral vein allows them to be effective and safe [1]. In the present case we had to deal with a patient with a very high risk of paradoxical embolism. Co-existing clotting disorder, a history of neurological incidents and the anatomy of the atrial septum were critical elements in the process of qualification for percutaneous PFO closure. Due to thrombosis of the inferior vena cava with prominent venous collaterals and dilatated hepatic veins, it was not possible to perform the procedure using the femoral venous approach or the transhepatic approach [2]. At the time of writing, there were only 2 publications on the use of the internal jugular venous access for percutaneous PFO closure. In the first publication, Sader et al. reported two cases of PFO closure performed using the internal jugular venous approach [3]. In both cases advancing the catheter through the PFO channel and implanting the occluder directly from the left atrium did not pose any major difficulties. In the second publication, a steerable system was used for occluder implantation [4]. According to our best knowledge, this is the first report of a PFO closure procedure with access through the internal jugular vein using standard implantation equipment and necessity to advance the guide wire and transseptal sheath into the left ventricle. Performing PFO closure using the right internal jugular venous approach is technically difficult but possible using standard equipment available in the majority of invasive cardiology centers. One of the most challenging stages is advancing the catheter through the PFO, which is physiologically directed towards the inferior vena cava, into the left atrium. This forced us to use a catheter routinely used for left coronary artery catheterization, the tip of which may be pointed towards the PFO channel. Furthermore, the use of a hydrophilic guidewire was crucial to probe the PFO. As we performed the procedure advancing the JL catheter was difficult but possible after minor maneuvers. However, securing the guidewire in the left atrium was a significant problem, which eventually required advancing the JL catheter into the left ventricle and subsequently protruding the guidewire, curved prior to the maneuver. This maneuver allowed for stable and secure insertion of the 9 Fr transseptal sheath, withdrawing it above the mitral valve and, finally, occluder implantation. We selected the Figulla Flex II PFO 23/25 occluder due to its unique attachment mechanism, which enables implantation at an acute angle to the delivery system. Conclusions To our knowledge this is the first report of a successful occluder implantation using the internal jugular venous approach, with the necessity to advance the guide wire and the transseptal sheath into the left ventricle. 126

In rare cases of an absolute indication for PFO closure and lack of access through the femoral veins, developing alternative techniques seems to be especially important. Because of the potential difficulties in performing the procedure using alternative approaches, their routine use is unlikely but it may have great importance in rare cases where using the transfemoral access is not possible. References 1. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092-100. 2. Hussain J, Strumpf R, Foroush A et al. Transhepatic approach to closure of patent foramen ovale. Tex Heart Inst J 2010; 37: 553-6. 3. Sader MA, De Moor M, Pomerantsev E, et al. Percutaneous transcatheter patent foramen ovale closure using the right internal jugular venous approach. Catheter Cardiovasc Interv 2003; 60: 536-9. 4. Hascoet S, Fraisse A, Elbaz M. Successful percutaneous transcatheted patent foramen ovale closure through the right internal jugular vein using a steerable catheter. Catheter Cardiovasc Interv 2013; 82: E598-602. 127